31 completed, 5 withdrawn, 4 terminated, 3 not yet recruiting. 21 Phase 1, 10 Phase 3, 7 Phase 2, 7 Phase 4, 1 Not applicable.
Follow Laboratorios Sophia S.A de C.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema PRO-169 - Immunogenicity, Anti-drug Antibodies (ADAs) | Phase 1 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | 60 | 2026-03-01 | 2026-03-13 |
| Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® PRO-240, Optive® - Dry Eye Disease, Dry Eye Sensation | Phase 1 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | 32 | 2026-01-30 | 2025-03-19 |
| Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. PRO-190, Systane Ultra® - Dry Eye, Dry Eyes Chronic | Phase 1 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | 32 | 2025-12-30 | 2025-03-19 |
| PRO-232 in Patients Subjected to Cataract Surgery Moxifloxacin / Dexamethasone Ophthalmic Solution, Placebo, Moxifloxacin Hydrochloride, Ophthalmic - Cataract Extraction | Phase 3 | Recruiting | Laboratorios Sophia S.A de C.V. | 134 | 2025-10-27 | 2025-12-26 |
| Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes Manzanilla Sophia®, Meticel Ofteno® 0.5% - Ophthalmological Agent Toxicity | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 167 | 2025-05-23 | 2026-04-08 |
| Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children. Alleance®, Placebo - Myopia, Myopia, Progressive | Phase 3 | Recruiting | Laboratorios Sophia S.A de C.V. | 123 | 2025-03-15 | 2025-03-21 |
| Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes. Manzanilla Sophia®, Meticel Ofteno® - Eye Strain, Eye Strain of Both Eyes | Phase 4 | Withdrawn | Laboratorios Sophia S.A de C.V. | 2025-02-11 | 2025-02-14 | |
| Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF PRO-229, Lagricel® Ofteno PF - Dry Eye Disease, Ocular Surface Disease | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 36 | 2024-05-16 | 2025-03-04 |
| Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. PRO-232, Placebo - Healthy | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 28 | 2024-02-08 | 2026-04-16 |
| Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects PRO-231, VIGAMOXI® - Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 37 | 2024-01-30 | 2025-06-15 |
| Safety and Tolerability of PRO-185 Naphazoline / Hypromellose Ophthalmic - Hyperemia Eye | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 22 | 2023-02-04 | 2025-07-17 |
| Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution Atropine Sulfate - Myopia | Phase 1 | Withdrawn | Laboratorios Sophia S.A de C.V. | 2023-02-01 | 2024-07-01 | |
| Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy Sodium Hyaluronate Ophthalmic 0.4%, Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15% - Photorefractive Keratectomy, Corneal De-epithelialization | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 96 | 2022-09-03 | 2026-04-07 |
| Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201 Atropine Sulfate - Myopia | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 29 | 2022-08-20 | 2026-02-05 |
| Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day - Dry Eye | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 141 | 2022-01-03 | 2026-03-03 |
| Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%, Sodium hyaluronate 0.15%, Sodium hyaluronate 0.4% - Dry Eye | Phase 4 | Completed | Laboratorios Sophia S.A de C.V. | 182 | 2021-12-09 | 2026-02-20 |
| Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost - Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | Terminated | Laboratorios Sophia S.A de C.V. | 28 | 2021-10-19 | 2026-05-07 |
| Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat. Sodium hyaluronate 3% - Age-related Cataract, Phacoemulsification | Not applicable | Completed | Laboratorios Sophia S.A de C.V. | 36 | 2021-09-07 | 2025-12-16 |
| Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema Bevacizumab, Lucentis® - Diabetic Macular Edema | Phase 3 | Completed | Laboratorios Sophia S.A de C.V. | 509 | 2021-05-24 | 2026-10-14 |
| Clinical Trial to Compare the Safety and Efficacy of Nanodrop® Nanodrop®, Systane Balance - Dry Eye | Phase 1 / Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 126 | 2020-12-01 | 2025-07-16 |
Showing 20 of 45. Sign in to see all of them.
Dry Eye Syndromes (13) · Conjunctivitis, Bacterial (5) · Glaucoma (5) · Glaucoma, Open-Angle (5) · Ocular Hypertension (4) · Cataract (3) · Myopia (3) · Conjunctivitis, Allergic (2) · Asthenopia (1) · Conjunctivitis (1) · Eye Pain (1) · Inflammation (1) · Myopia, Degenerative (1) · Pterygium (1)
Moxifloxacin (3) · Propylene Glycol (3) · Atropine (2) · Brimonidine Tartrate (2) · Chondroitin Sulfates (2) · Gatifloxacin (2) · Hyaluronic Acid (2) · Latanoprost (2) · Ophthalmic Solutions (2) · Timolol (2) · bromfenac (2) · chondroitin sulfate, sodium hyaluronate drug combination (2) · dorzolamide (2) · dorzolamide-timolol combination (2) · pazufloxacin (2)
Mexico (38) · Colombia (1)
Leopoldo Baiza, MD (3) · Leopoldo M Baiza-Duran, MD (2) · Alejandra Sanchez-Rios, MD (1) · Alfredo Lizarraga-Corona, MD (1) · Mauricio Casillas, MD (1) · Miriam Becerra-Cotta, MD (1)
PMID 34707360, PMID 27645318, PMID 29680880, PMID 32606573, PMID 36046598, PMID 37077305, PMID 37543959, PMID 39233999, PMID 40750915, PMID 40873654, PMID 41737851